The mortality is low, but significant acute morbidity and chronic complications cause APP to be a leading cause of asparaginase discontinuation, this being possibly associated with an increased risk of relapse, given the core importance of asparaginase in ALL treatment.13,16,17. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.